Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of SGLT2 Inhibitors in Improving Heart Failure in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Severe Renal Insufficiency

NCT05737186 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05737186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of SGLT2 Inhibitors in Improving Heart Failure in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Severe Renal Insufficiency
Lead sponsor
Peking University People's Hospital
Phase
Phase 4
Overall status
Terminated
Start date
March 9, 2023
Completion date
April 16, 2024
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction, renal insufficiency, chronic